Surrozen, Inc (SRZN) News
Filter SRZN News Items
SRZN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest SRZN News From Around the Web
Below are the latest news stories about SURROZEN INC that investors may wish to consider to help them evaluate SRZN as an investment opportunity.
SRZN Stock Earnings: Surrozen Beats EPS for Q2 2023SRZN stock results show that Surrozen beat analyst estimates for earnings per share the second quarter of 2023. |
SRZN Stock Earnings: Surrozen Misses EPS for Q1 2023SRZN stock results show that Surrozen missed analyst estimates for earnings per share the first quarter of 2023. |
SRZN Stock Earnings: Surrozen Misses EPS for Q3 2023SRZN stock results show that Surrozen missed analyst estimates for earnings per share the third quarter of 2023. |
Surrozen Provides Third Quarter 2023 Financial ResultsExpect to announce data from SZN-043 Phase 1a clinical trial in patients with chronic liver disease and in healthy volunteers in Q1 2024 Expect to announce data from SZN-1326 Phase 1a clinical trial in healthy volunteers in Q1 2024 Initiating Phase 1b studies in 2024 for SZN-043 in severe alcoholic hepatitis and SZN-1326 in moderate to severe ulcerative colitis Strengthened portfolio through two granted patents from the USPTO related to key discoveries involving the WNT pathway and its modulatio |
Surrozen Provides Second Quarter 2023 Financial ResultsSZN-043 Phase 1a clinical trial in patients with chronic liver disease and in healthy volunteers continues to enroll with safety data expected by the end of 2023 SZN-1326 Phase 1a clinical trial in healthy volunteers continues to enroll with safety data expected by the end of 2023 Corporate prioritization efforts expected to provide cash runway extension into 2025 SOUTH SAN FRANCISCO, Calif., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company |
Surrozen Publishes Study in Nature Communications Demonstrating the Promise of a Fzd4 Wnt Antibody in Treating Ischemic StrokeIn a preclinical model of ischemic stroke, systemic delivery of a selective Fzd4 Wnt antibody strongly reduced blood-brain-barrier leakage, death of surrounding brain tissue, tissue swelling, while improving neurologic scoreResults highlight potential of selective Fzd4 Wnt antibody for central nervous system disorders involving an abnormal blood-brain-barrier SOUTH SAN FRANCISCO, Calif., June 05, 2023 (GLOBE NEWSWIRE) -- Surrozen, Inc. (Nasdaq: SRZN), a company pioneering targeted therapeutics t |
Surrozen Provides First Quarter 2023 Financial Results and Corporate and Pipeline UpdatesEnrollment ongoing in SZN-043 Phase 1a clinical trial in people with chronic liver disease and in healthy volunteers with safety data expected by the end of 2023 Enrollment ongoing in SZN-1326 Phase 1a clinical trial in healthy volunteers with safety data expected by the end of 2023 SOUTH SAN FRANCISCO, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tiss |
Surrozen Strengthens Board of Directors with the Appointment of Eric BjerkholtSOUTH SAN FRANCISCO, Calif., April 05, 2023 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today announced that Eric Bjerkholt has been appointed to the Board of Directors. Surrozen’s Board of Directors now includes nine members with extensive experience across diverse disciplines in biotechnology and pharmaceutical development. Mr. Bjerkholt |
Surrozen, Inc. (NASDAQ:SRZN) Q4 2022 Earnings Call TranscriptSurrozen, Inc. (NASDAQ:SRZN) Q4 2022 Earnings Call Transcript March 25, 2023 Operator: Good afternoon, and welcome to the Surrozen Corporate Update Conference Call. My name is Josh, and I will be your manager for this call. I will now turn the call over to Craig Parker, CEO of Surrozen to begin the call. Craig Parker: […] |
Surrozen Provides Fourth Quarter and Full Year 2022 Financial Results and Update on Clinical Pipeline and Corporate ProgressEnrolled first patient in SZN-043 Ph 1a clinical trial in chronic liver disease with data expected by the end of 2023 Expect to begin SZN-043 Ph1b clinical trial in severe alcoholic hepatitis in 2024 with proof-of-concept data expected in the second half of 2024 Expect to reinitiate SZN-1326 Ph1a clinical trial in healthy volunteers by mid-2023 with data expected by the end of 2023 Anticipate potential proof-of-concept data for SZN-1326 in ulcerative colitis in the second half of 2024 Expect to |